

Japan's ThinkCyte expands product portfolio to drive innovation in drug discovery and disease research

29 January 2025 | News

Providing the tools to accelerate discoveries in disease understanding and drug discovery to improve lives



Japan-based startup ThinkCyte, a biotechnology company pioneering novel artificial intelligence (AI)-based cell analysis and sorting instruments, will begin the pre-commercial launch of its new cell analysis platform, VisionCyte.

The announcement coincides with the 2025 Society for Laboratory Automation and Screening (SLAS) conference in San Diego, US from January 27-30, 2025, where VisionCyte was named a finalist for the 2025 New Product Award. The launch of VisionCyte extends ThinkCyte's product portfolio of life science research platforms beyond VisionSort, the company's flagship product launched in 2023 and adopted by leading biopharmaceutical companies and academic institutions worldwide.

The VisionCyte platform leverages high resolution morphological profiling, high-throughput capabilities, and advanced AI analysis to uncover novel biomarkers and facilitate the discovery of new and diversified hits and targets for drug discovery. The full commercial rollout of VisionCyte will occur in 2025, with an initial line of customer ready units available in H2 2025. The company also announced the launch of its Celluminate cell tracking kits, compatible with both VisionSort and VisionCyte, for enabling discovery applications in areas where existing cell surface cell markers are limited such as specific hematological conditions, stem cell research, and age-related diseases.